Drug
Sitravatinib
Sitravatinib: highest development phase Phase 3, developed by BeiGene, Mirati Therapeutics. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BeiGene, Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sitravatinib NCT05564338 | Phase 3 | Hepatocellular Carcinoma |
| Sitravatinib NCT04887870 | Phase 2/3 | Advanced or Metastatic Solid Malignancies |
| Sitravatinib NCT05461794 | Phase 2 | Esophageal Squamous Cell Carcinoma |
| Sitravatinib NCT03680521 | Phase 2 | Clear Cell Renal Cell Carcinoma |
| Sitravatinib NCT03606174 | Phase 2 | Urothelial Carcinoma |
| Sitravatinib NCT03941873 | Phase 1/2 | Carcinoma, Hepatocellular |
| Sitravatinib NCT04887194 | Phase 1 | Advanced Solid Tumor |
| sitravatinib NCT04772612 | Phase 1 | Hepatic Impairment |
| Sitravatinib NCT04472650 | Phase 1 | Tumor |
| Sitravatinib NCT04935112 | Phase 1 | Healthy Adults |
Latest
No recent events.
Follow Sitravatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.